Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BHV-1400 in the Treatment of IgA Nephropathy

NCT07642050 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.

NCT NCT07642050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07642050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BHV-1400 in the Treatment of IgA Nephropathy
Lead sponsor
Biohaven Therapeutics Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
October 31, 2029
Enrollment
420 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy